Sanofi inks a Korean alliance to develop a pneumococcal vaccine

Sanofi ($SNY) has partnered with South Korea's SK Chemicals to develop, produce and market a pneumococcal conjugate vaccine. The French Big Pharma is paying SK Chemicals $23 million up front, after which both companies will invest in the project. If development is successful, SK Chemicals will manufacture the vaccine at its plant in South Korea and retain exclusive rights to the product in its home market. The partners will share profits generated outside of Korea. Release

Suggested Articles

BN will use its proprietary MVA-BN platform to develop a vaccine against three strains of the potentially deadly mosquito-borne virus.

BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.

The two new grants will support development of universal flu and malaria vaccines leveraging CureVac’s RNActive mRNA-based platform.